EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million

EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Capital Increase
Marinomed Biotech AG has decided to conduct a cash capital increase to
cover short-term capital requirements of approximately EUR 2 million

19-March-2026 / 16:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by [1]EQS News – a service of
[2]EQS Group.
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

Ad hoc announcement

Marinomed Biotech AG has decided to conduct a cash capital increase to
cover short-term capital requirements of approximately EUR 2 million

 

Korneuburg, Austria, March 19, 2026

The Executive Board of Marinomed Biotech AG (“Company”) resolved today,
with the approval of the Supervisory Board, to carry out a capital
increase against cash contributions—while preserving the subscription
rights of existing shareholders—by partially utilizing the authorized
capital provided for in Section 5(6) of the Articles of Association, in
order to meet short-term capital requirements, and to increase the share
capital from the current EUR 1,839,940 by up to EUR 459,985 through the
issuance of up to 459,985 new no-par value bearer shares (“New Shares”)
with a notional proportionate amount of the share capital of EUR 1.00 per
share to up to EUR 2,299,925 (the “Capital Increase”). Existing
shareholders of the Company (“Existing Shareholders”) will be granted
subscription rights (“Subscription Rights”) on a 4:1 basis, i.e., for
every four existing shares, one New Share may be subscribed for at a
subscription price of EUR 14.00 per New Share (“Subscription Price”). The
goal of the transaction is to generate gross proceeds of at least EUR 2
million.

Because the Company has not yet received sufficient payments from the
transfer of the Carragelose business to Unither Pharmaceuticals
(“Unither”), the Company has a short-term capital requirement to cover its
anticipated liquidity needs of approximately EUR 2 million until mid of
the fiscal year 2026. The net proceeds from the capital increase are
therefore to be used to fulfill the restructuring plan and close the
financing gap.

The Company will make use of the prospectus exemptions provided for in
Article 1(4)(db) and Article 1(5)(ba) of Regulation (EU) 2017/1129
(“Prospectus Regulation”), as amended, in connection with the offering of
the New Shares and the admission of the New Shares to trading on the
Vienna Stock Exchange. The document required for this purpose pursuant to
Annex IX of the Prospectus Regulation will be filed in electronic form
with the Financial Market Authority (FMA), as the competent authority of
the home Member State, prior to the commencement of the public offering
and will be made available to the public at the same time as it is filed
with the FMA via the website www.marinomed.com.

The record date for the entitlement of existing shareholders to subscribe
for New Shares is March 25, 2026, at 11:59 p.m. CEST (“Record Date”). The
subscription period is scheduled to begin on March 26, 2026 9:00 a.m.
Central European Time and is expected to end on April 9, 2026 5:40 p.m.
Central European Time, although the subscription period may be extended at
any time. The subscription rights will not be tradable on the Vienna Stock
Exchange. Any New Shares not subscribed for through the exercise of
subscription rights in connection with the subscription offer (“Rump
Shares”) will be offered following the subscription offer as part of a
prospectus-exempt private placement (“Rump Placement”) to eligible
institutional investors and selected non-institutional investors within
the European Economic Area at the Subscription Price. A binding commitment
has been received from an institutional investor who, as of today, does
not yet hold any shares in the Company, to subscribe for and acquire New
Shares in the total amount of EUR 1 million at the Subscription Price as
part of the Rump Placement.

This announcement is made in accordance with Article 17 of the Market
Abuse Regulation (EU) No. 596/2014.

Disclaimer:

The New Shares and Subscription Rights have not been and will not be
registered under any foreign securities laws—in particular under the U.S.
Securities Act of 1933, as amended (“Securities Act”) – with foreign
securities authorities and may not be offered or sold, in particular in
the United States of America (“U.S.”), without registration or an
exemption from the registration requirements under the Securities Act.
This announcement is not intended for distribution in the U.S. or within
the U.S. and may not be distributed or forwarded to publications with
general circulation in the U.S. Foreign shareholders may be subject to
restrictions on the exercise of their subscription rights. Foreign
shareholders are therefore urged to inform themselves of the restrictions
applicable to them regarding the exercise of subscription rights. This
announcement is neither an offer to sell nor a solicitation of an offer to
subscribe for or purchase securities in countries where such an offer or
solicitation is legally prohibited.

+++ End of ad-hoc announcement +++

 

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.

 

For further inquiries contact:

Marinomed Biotech AG  
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [3]pr@marinomed.com
E-Mail: [4]ir@marinomed.com

 

Disclaimer 

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only. 

End of Inside Information

══════════════════════════════════════════════════════════════════════════

19-March-2026 CET/CEST News transmitted by [5]EQS Group

View original content: [6]EQS News

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2294718

 
End of Announcement EQS News Service

2294718  19-March-2026 CET/CEST

https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2294718&application_name=news&site_id=apa_ots_austria~~

References

~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2294718&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
3. pr@marinomed.com
4. ir@marinomed.com
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2294718&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
6. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=e5732365b967a22399223cc381714089&application_id=2294718&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender